Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 179 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Thrombosis Clear all
Recruiting No phase listed Observational

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

NCT04947657
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational

Redesigning Cardiac Surgery to Reduce Neurologic Injury

NCT00432536
View directory record Official record
Conditions
Cardiovascular Disease, Surgery
Interventions
Quality improvement intervention
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
40 Years to 89 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
3
States / cities
Portland, Maine • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

NCT00329433
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Desirudin (Iprivask™), Heparin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational

COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications

NCT04535128
View directory record Official record
Conditions
Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 4 Interventional Results available

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

NCT02486367
View directory record Official record
Conditions
Aortic Stenosis, Inflammation, Thrombosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational

HemoSonics - UTMB Cardiac Surgery Study

NCT03988465
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Prospective Randomized On-X Versus SJM Evaluation Trial

NCT00639782
View directory record Official record
Conditions
Heart Valve Disease
Interventions
On-X Heart valve replacement, SJM Heart valve replacement
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Honolulu, Hawaii • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 23, 2026, 8:20 PM EDT
Not listed No phase listed Observational

EKG Criteria and Identification of Acute Coronary Occlusion

NCT03863327
View directory record Official record
Conditions
Acute Coronary Syndrome, STEMI, STEMI - ST Elevation Myocardial Infarction, Acute Coronary Artery Thrombosis (Diagnosis), NSTEMI - Non-ST Segment Elevation MI, Non-ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction, Non ST Segment Elevation Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction (nSTEMI), Non STEMI
Interventions
No intervention
Other
Lead sponsor
Stony Brook University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational

Prehospital Translation of Chest Pain Tools

NCT03494556
View directory record Official record
Conditions
Acute Coronary Syndrome, Pulmonary Embolism
Interventions
Data Collection
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Fayetteville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Jul 23, 2026, 8:20 PM EDT
Withdrawn Not applicable Interventional

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE

NCT04855370
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Embolus/Emboli, Pulmonary Disease, Pulmonary Embolism and Thrombosis, Pulmonary Embolism Subacute Massive, Pulmonary Embolism Acute Massive
Interventions
Non-invasive hemodynamic measurements
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Testing Strategies to Improving Warfarin Adherence

NCT00622102
View directory record Official record
Conditions
Atrial Fibrillation, Deep Venous Thrombosis, Dilated Cardiomyopathies
Interventions
Lottery arm (Lottery and Med-eMonitor), Non-Lottery (Med-eMonitor only)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.

NCT00209144
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Intensive insulin therapy
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564
View directory record Official record
Conditions
Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions
Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
135
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational

Patient Centered Machine Learning Model for Bleeding and Ischemic Risk

NCT06089304
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Percutaneous coronary intervention
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 99 Years
Enrollment
19,000 participants
Timeline
2008 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 23, 2026, 8:20 PM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 23, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

NCT06576427
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Vertex Pulmonary Embolectomy System
Device
Lead sponsor
Jupiter Endovascular
Industry
Eligibility
18 Years to 79 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
Hartford, Connecticut • Pensacola, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 8:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers

NCT07159269
View directory record Official record
Conditions
Cardiovascular Disease Acute, Emergency Department Patient, Heart Failure Acute, Pulmonary Embolism (Diagnosis), Point of Care Ultrasound (POCUS), Cardiac Tamponade, Pericardial Effusion, Diagnostic Imaging, Medical Training, Implementation Science
Interventions
Cardiac point-of-care ultrasound (POCUS) training and clinical pathway
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 8:20 PM EDT